Allogeneic Hematopoietic Cell Transplantation with Full-Intensity Conditioning for Adult Acute Lymphoblastic Leukemia: Results from a Single Center, 1998-2006  by Doney, Kristine et al.
From the 1
search
tics,
Cente
Financial d
Correspon
Hutch
North
Received A
 2011 Am
1083-8791
doi:10.101Allogeneic Hematopoietic Cell Transplantation
with Full-Intensity Conditioning for Adult Acute
Lymphoblastic Leukemia: Results from a Single
Center, 1998-2006
Kristine Doney,1,3 Ted A. Gooley,1,2 H. Joachim Deeg,1,3
Mary E. D. Flowers,1,3 Rainer Storb,1,3 Frederick R. Appelbaum1,3A retrospective analysis identified 161 consecutive adults with acute lymphoblastic leukemia who underwent
allogeneic hematopoietic cell transplantation (HCT) with full-intensity (myeloablative) conditioning between
1998 and2006.Medianpatient agewas 36.1 years. Seventy-six patientswere in first complete remission (CR1),
and 85 were in second or greater CR or in relapse. Fifty-nine patients had Philadelphia chromosome–positive
acute lymphoblastic leukemia. A total of 159 patients received chemotherapy plus total body irradiation for
conditioning. Graft-versus-host disease prophylaxis included a calcineurin inhibitor plus methotrexate or my-
cophenolatemofetil. Sixtyof the donorswere related, and101were unrelated. A total of 110patients received
granulocyte-colony stimulating factor–stimulated peripheral blood, 47 received bone marrow, and 4 received
cord blood as the stem cell source. Fifty-five patients relapsed at a median of 231 days after transplantation.
The estimated 5-year probabilities of relapse-free survival, relapse, and nonrelapse mortality were 47%, 30%,
and 29%, respectively. Bymultivariate analyses, transplantationwhile inCR1was themost important predictor
of successful transplantation. Pretransplantation evidence ofminimal residual disease, especially as detected by
flowcytometric analysis, was associatedwith both loweroverall survival and lower relapse-free survival. Com-
paredwith a similarcohort of patients undergoing transplantation between1990 and 1997, overall survivalwas
similar for patients undergoing transplantation in CR1, with lower nonrelapse mortality being offset by higher
rates of relapse in patients who underwent transplantation more recently.
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For adults with acute lymphoblastic leukemia
(ALL), the indications for and timing of allogeneic he-
matopoietic cell transplantation (HCT) continue to be
debated [1-3]. Over the past 20-25 years, conditioning
regimens, graft-versus-host disease (GVHD) prophy-
laxis and treatment, donor selection, and supportive
care have been continually refined in an effort to
improve transplantation outcomes. The methodology
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6/j.bbmt.2010.12.699tinues to evolve, with sensitive flow cytometrymethods
and polymerase chain reaction (PCR) monitoring of
molecular markers redefining relapse [4,5]. Criteria
for classifying chronic GVHD also have been revised
and await validation [6]. Given these modifications,
we performed a retrospective analysis of consecutive
adult patients with ALL who underwent allogeneic
HCT with full-intensity conditioning between 1998
and2006.Multivariate analyseswere performed, focus-
ing on clinical factors as well as indicators of MRD for
their association with transplantation outcome. Those
resultswere then comparedwith findings froma similar
cohort of patients who underwent HCT between 1990
and 1997 published previously [7].MATERIALS AND METHODS
Patient and Disease Characteristics
Patients included in this analysis had a diagnosis of
ALL, were age $18 years, received a full-intensity
conditioning regimen, and underwent HCT between1187
Table 1. Recipient and Donor Characteristics
Characteristic Number* %
Number of patients 161
Median patient age, years (range) 36.1 (18.1-61.8)
#35 years 75 47
>35 years 86 53
Donor–recipient sex match†
M/M 54 33
M/F 28 17
F/F 34 21
F/M 43 27
F + M/M 1 1
M + M/F 1 1
Immunophenotype
B cell, immature 137 85
B cell, maturity unknown 3 2
T cell 17 10
Unknown 4 2
Cytogenetics
Normal 35 22
Ph+‡ 59 37
Other unfavorable§ 15 9
Miscellaneous¶ 39 24
Unknown 13 8
Median WBCs  1029/L at diagnosis,
(range) (n 5154)
16.5 (0.4-683)
Extramedullary disease**
CNS only 16 10
CNS + other sites 3 2
Testis 3 2
Other 2 1
None 137 85
Median disease duration, mo (range) 8.6 (2.4-216.3)
Disease status at HCT
CR1 76 47
$CR2 57 35
Relapse 28 18
MRD pre-HCT (59 patients in CR)††
Karyotype
Abnormal 35 59
Normal 22 37
ND 2 4
Flow cytometry
Abnormal 26 44
Normal 33 56
FISH
Abnormal 4 7
Normal 21 36
ND 34 57
Median donor age, years (range)‡‡ 35 (4-65)
Donor–recipient HLA compatibility
Related/matched 55 34
Related/mismatched 5 3
Unrelated/matched 62 39
Unrelated/mismatched 39 24
Donor–recipient CMV serology
-/- 55 34
-/+ 36 23
+/- 21 13
+/+ 49 30
CNS indicates central nervous system; ND, no data.
*Number of patients unless specified otherwise.
†Of 4 cord blood transplantations, 2 were single-unit transplantations
and 2 were double-unit transplantations.
‡Ph+ includes patients with a t(9;22) only, t(9;22) plus additional clonal
abnormalities, or BCR/ABL+ by FISH analysis.
§Includes -7, +8, or 11q23 rearrangement.
¶Other clonal abnormalities.
**Extramedullary disease occurring before or at the time of HCT.
††Pretransplantation studies are studies done near the time of the con-
ditioning regimen. Eleven of the 59 patients had 2 abnormal markers
(flow cytometry plus abnormal karyotype or abnormal FISH results).
‡‡n 5 158 (cord blood transplant donors excluded).
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formed consent was obtained from all patients and do-
nors using forms approved by the Fred Hutchinson
Cancer Research Center’s Institutional Review Board.
Pretransplantation recipient characteristics are
summarized in Table 1. Median age was 36.1 years
(range, 18.1-61.8 years). Recipients were classified as
having B cell or T cell ALL based on immunopheno-
typing results. B cell maturity at diagnosis was charac-
terized as immature or mature; immature B cells
expressed TdT and/or CD34 and/or CD10, whereas
mature B cells expressed CD20, CD22, or SIg and
did not express any immature markers [8]. Myeloid
markers were defined as the expression of CD13 or
CD33. Cytogenetic studies were performed on bone
marrow (BM) or peripheral blood stem cells (PBSCs).
Karyotypes were classified as normal, Philadelphia
chromosome positive (Ph1), other unfavorable abnor-
malities (-7,18, or 11q23 rearrangement), or miscella-
neous abnormalities [9]. Patients were considered to
be Ph1 if conventional cytogenetics were positive for
t(9;22) or if fluorescence in situ hybridization (FISH)
studies were positive for the BCR/ABL rearrange-
ment. Too few PCR studies were done before trans-
plantation to be informative. Complete remission
(CR) was defined as \5% blasts by morphology in
BM specimens that were .20% cellular.
Donor Selection and Stem Cell Collection
Donor characteristics are summarized in Table 1.
Median donor age, excluding the 4 cord blood donors,
was 35 years (range, 4-65 years). HLA compatibility
was determined by medium-resolution molecular
methods for HLA-A, -B, -C, and -DQB1 and by
DNA sequencing methods for -DRB1. Fifty-five
transplants were from anHLA-matched related donor,
5 were from an HLA-mismatched related donor, 62
were from an HLA-matched unrelated donor, and 39
were from an HLA-mismatched unrelated donor.
The stem cell source was BM in 47 patients, granulo-
cyte-colony stimulating factor (G-CSF)-stimulated
PBSCs in 110 patients, and umbilical cord blood in
4 patients.
Transplantation Regimens
Table 2 summarizes the preparative regimens,
stem cell doses, and posttransplantation immunosup-
pression used. Total body irradiation (TBI) was deliv-
ered by dual opposing cobalt sources for patients
undergoing HCT through mid-May 2000 (n 5 38)
and by a linear accelerator (18-MV photons) with
lung shielding for subsequent patients (n 5 121).
Male patients also received a 400-cGy testicular boost.
The majority of patients (n5 109) received cyclophos-
phamide (Cy) plus 12.0 Gy of fractionated TBI.
Eighty-seven of these 109 patients received Cy 60
Table 2. HCT Regimens and Outcome Data
Parameter Number* %
Preparative regimen
Cy, 12.0 Gy TBI 109 68
Cy, 13.2 Gy TBI 45 28
VP16, 12-13.2 Gy TBI 4 2
Other 3 2
Median stem cell dose (range)†
BM  1028 TNCs/kg (n 5 42) 3.08 (0.89-9.01)
PBSCs  1026 CD34+ cells/kg
(n 5 109)
8.08 (2.87-32.15)
Cord blood  1027 TNCs/kg
(n 5 4)
0.42 (0.2-0.5)
GVHD prophylaxis
CSP + MTX 99 61
FK506 + MTX 37 23
FK506 + MMF 7 4
CSP + MMF 8 5
CSP + MTX + other 4 3
MTX, sirolimus, + FK506 5 3
None 1 1
aGVHD (n 5 152)
Grade 0-I 25 17
Grade II-IV 127 83
Median day of onset of grade II-IV
aGVHD (range)
21 (6-102)
Chronic GVHD 80
Relapse (n 5 55)
Median day of relapse (range) 231 (19-2298)
Survival
Patients alive 63 39
Patients dead 98 61
Causes of death# (n 5 98)
Relapse 52 53
DAD/ARDS 19 19
Infection 13 13
cGVHD with or without infection 9 9
aGVHD with or without infection 3 3
Graft failure plus infection 2 2
DAD/ARDS indicates diffuse alveolar damage/adult respiratory distress
syndrome; TNC, total nucleated cells.
*Number of patients unless specified otherwise.
†The stem cell dose was not available for 5 patients who received BM
and 1 patient who received PBSCs.
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tients received a single dose of Cy 45 mg/kg i.v.,
followed by a second dose that was adjusted based on
therapeutic drug monitoring after the first dose [10].
The mean second dose of Cy for these 22 patients
was 66 mg/kg. All patients received at least 6 doses
of prophylactic intrathecal methotrexate (MTX) (12
mg/dose), with 2 doses given before transplantation
and 4 doses given after transplantation, beginning on
day 30 posttransplantation and continuing biweekly
thereafter. Eleven patients with Ph1 disease partici-
pated in a posttransplantation trial of imatinib. Some
84% of the patients received either cyclosporine
(CSP) and MTX (n 5 99) or tacrolimus (FK506) and
MTX (n 5 37) for GVHD prophylaxis [11-13].
Engraftment, GVHD, and Quality of Life
The time to myeloid engraftment was defined as
the first of 3 consecutive days with an absolute neutro-
phil count $0.5  109/L. Platelet engraftment wasdefined as the first of 7 consecutive days with an un-
transfused platelet count $20  109/L. Acute GVHD
(aGVHD) was diagnosed and graded according to
previously published criteria [14]. All patients who en-
grafted (n 5 153) were considered evaluable for
aGVHD. Chronic GVHD (cGVHD) was defined by
National Institutes of Health (NIH) consensus crite-
ria, with all included patients requiring systemic im-
munosuppressive therapy [6]. The NIH criteria were
applied retrospectively; subcategories of cGVHD
could not be assessed because of incomplete data
[15]. Karnofsky scores were obtained from patients
or from referring physicians as part of yearly long-
term follow-up questionnaires [16].
Supportive Care
All red cell and platelet transfusions were irradi-
ated. All patients who were cytomegalovirus (CMV)-
negative before transplantation received ‘‘CMV-safe’’
blood products [17]. Routine antibacterial, antifungal,
and antiviral prophylaxis included levofloxacin until
the occurrence of neutrophil engraftment, fluconazole
for a minimum of 75 days post-HCT, and acyclovir or
valacyclovir for 1 year post-HCT. Trimethoprim-
sulfamethoxazole or dapsone for Pneumocystis jiroveci
prophylaxis was administered pre-HCT and after en-
graftment, for a minimum of 6 months. Surveillance
testing for CMV reactivation was performed weekly
for a minimum of 100 days post-HCT, and ganciclovir
or foscarnet therapy was started in patients who dem-
onstrated an increase in viral copy numbers [17].
G-CSFwas not used on a routine basis, but was admin-
istered to neutropenic patients based on their clinical
condition. Since 2003, all patients were also treated
prophylactically with ursodiol for 90 days post-HCT
[18,19].
Statistical Analysis
Outcomes evaluated in univariate analyses in-
cluded death, nonrelapse mortality (NRM), relapse,
and relapse-free survival (RFS). Factors evaluated in
univariate analyses for association with outcomes in-
cluded year of transplantation, recipient age at trans-
plantation, recipient sex, donor–recipient sex match,
disease parameters (i.e., white blood cells [WBCs] at
diagnosis, cytogenetic markers, leukemic phenotype,
presence of myeloid markers, cerebrospinal fluid in-
volvement, and extramedullary disease),minimal resid-
ual disease (MRD) pretransplantation (morphological,
cytogenetic, or flow cytometricmarkers), donor–recip-
ient CMV serology, donor–recipient HLA matching,
stem cell source (BM or PBSCs), stem cell dose,
GVHD prophylaxis, aGVHD, and cGVHD.
Estimates of the probability of overall and RFS
were obtained using the Kaplan-Meier method [20].
NRM and relapse were summarized using cumulative
1190 Biol Blood Marrow Transplant 17:1187-1195, 2011K. Doney et al.incidence estimates, with relapse considered a compet-
ing risk for NRM and NRM considered a competing
risk for relapse [21]. Cox regression models were
used to examine the association of various factors
with the outcomes of overall mortality, NRM, relapse,
and cGVHD [22]. Logistic regression was used to do
the same for the endpoints grade II-IV and grade III-
IV aGVHD. Multivariable regression models were
fit using stepwise regression, with entry and exit P
values of .10. All two-sided P values resulting from re-
gression models were estimated using the Wald test,
with no adjustments made for multiple comparisons.RESULTS
Engraftment
A total of 153 patients (95%) achieved a sustained
absolute neutrophil count of$0.5 109/L at a median
time of 18 days (range, 3-35 days) post-HCT. The re-
maining 8 patients died early, at a median of 16.5 days
(range, 8-60 days) post-HCT. A total of 131 patients
achieved a self-sustained platelet count of $20 
109/L at a median time of 15 days (range, 8-60 days).
Two patients who did not achieve this level of platelet
engraftment before day 100 were alive at 774 and 796
days post-HCT. Twenty-two patients died between
days 5 and 65 without platelet engraftment, and 6 pa-
tients died after day 100 without evidence of platelet
engraftment before discharge.
Regimen-Related Toxicity
The cumulative incidence of NRM before day 100
for all 161 patients was 19%. NRM at 5 years was sig-
nificantly lower (P 5 .07) in patients who underwent
HCT while in first CR (CR1) (21%) compared with
those who did so while in second or greater CR
($CR2) (35%) or in relapse (46%) (Figure 1).Figure 1. Cumulative incidence of NRM in 161 adult patients with ALL
according to disease status at the time of HCT. The cumulative incidence
of NRM at 5 years post-HCTwas 21% for patients in CR1, 35% for those
in $CR2, and 46% for those in relapse.GVHD
Of the 152 patients graded for aGVHD, 127 (84%)
developed grade II-IV aGVHD at a median of 21 days
(range, 6-102 days) post-HCT. Eight of the 9 patients
who were not graded died on or before day 35; the
ninth patient, who had no documented aGVHD
assessment, died on day 204. The high incidence of
aGVHD at our center has been noted previously and
associated with high diagnostic sensitivity and in-
creased awareness of upper gut GVHD [23]. Of 125
patients who were evaluable for cGVHD, 80 (64%)
developed cGVHD based on NIH consensus criteria.Relapse
Fifty-five patients relapsed, at a median time of 231
days (range, 19-2298 days) post-HCT. Seventeen pa-
tients relapsed more than 1 year post-HCT, with the
latest relapse occurring at 6.3 years post-HCT. The
cumulative incidence of relapse at 5 years for all pa-
tients was 35%. The probability of relapse was greater
in those patients who underwent HCTwhile in relapse
(40%) compared with those who underwent HCT
while in CR1 (32%) or in $CR2 (37%) (Figure 2).Survival and Causes of Death
Sixty-three patients were alive and 98 had died at
the time of the writing of this report. The actuarial sur-
vival at 5 years was 38% for all 161 patients. Survival
and RFS were significantly associated with disease sta-
tus at the time of HCT, with patients undergoing
HCT while in CR1 having a 5-year RFS of 47%
(Figure 3). Survival for patients with Ph1 ALL was
comparable to that of patients with normal cytogenet-
ics (42% vs 44% at 5 years; Figure 4). Of the 32
patients who survived for .5 years, 28 had self-
assessment of performance at varying dates of last con-
tact. The median Karnofsky score was 90% (range,Figure 2. Cumulative incidence of relapse for 161 adult patients with
ALL according to disease status at the time of HCT. The probability of
relapse at 5 years post-HCTwas 32% for patients in CR1, 37% for those
in $CR2, and 40% for those in relapse.
Figure 3. RFS for 161 adult patients with ALL according to disease sta-
tus at the time of HCT. RFS at 5 years post-HCTwas 47% for patients in
CR1, 28% for those in $CR2, and 13% for those in relapse.
Figure 4. Actuarial survival for 148 adult patients with ALL based on
cytogenetic markers of disease. Survival at 5 years post-HCTwas 44%
for patients with normal cytogenetics, 42% for Ph1 patients, 13% for pa-
tients with other unfavorable cytogenetics, and 33% for patients with
miscellaneous clonal abnormalities.
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years) post-HCT. Physician-assigned scores were
available for 25 of these 32 patients. The median phy-
sician-assigned score was 100% (range, 70%-100%) at
a median time of 6.2 years (range, 1.5-11.5 years) post-
HCT. The most frequent cause of death was recurrent
ALL (n 5 52). Other causes of death are summarized
in Table 2.Prognostic Factors
Univariate analyses
Table S1 (available at.www.bbmt.org) details the
results of the univariate analyses. Disease status at the
time of HCT was statistically significantly associated
with all endpoints, with patients undergoing HCT
while in CR1 having better survival and RFS, lower
NRM, and lower relapse rates. More recent HCT
was associated with both improved survival and RFS
and a lower relapse rate. There was a trend for
opposite-sex donor–recipient pairs to adversely affect
survival and relapse rates. Patient age, sex,WBC count
at diagnosis (in patients with B cell ALL), Ph1 cytoge-
netics, immunophenotype, myeloid markers (in pa-
tients with B cell ALL), stem cell source, BM or
PBSC cell dose, donor–recipient HLA typing, andTable 3. Multivariate Analyses
Endpoint Variable
Overall mortality CR1
Cytometric CR pre-HCT
RFS CR1
Cytometric CR pre-HCT
Donor–recipient CMV serology mismatch pre-HC
Year of HCT
Relapse Cytometric CR pre-HCT
Year of HCT
NRM CR1
Donor–recipient CMV serology mismatch pre-HCGVHD prophylaxis were not statistically significantly
correlated with outcome.
All markers of active disease pre-HCT were
strongly associated with decreased survival, and the
majority of these markers were correlated with de-
creased RFS and increased NRM. Persistent disease
pre-HCT, as documented by morphology, cytogenet-
ics, or flow cytometry, also was statistically signifi-
cantly associated with a greater risk of relapse after
HCT, with flow cytometry having the strongest asso-
ciation (P 5 .009).
Severe (grade III-IV) aGVHD, modeled as a time-
dependent covariable, was associated with a 2.6-fold
increase in mortality and a .7-fold increase in NRM
compared with patients who did not develop aGVHD.
Whereas grade III-IV aGVHD was associated with
a lower relapse rate, patients with severe aGVHD of-
ten die early after HCT, before being at risk for re-
lapse. Chronic GVHD, either alone or together with
grade II-IV aGVHD, was not significantly associated
with any of the 4 endpoints evaluated.
Multivariate analyses
Results of the multivariate Cox regression analyses
are presented in Table 3. Undergoing HCT while in
CR1 remained significantly associated with increasedHazard Ratio P Value 95% CI
0.55 .007 0.36-0.85
0.55 .005 0.36-0.83
0.67 .06 0.43-1.02
0.55 .006 0.37-0.84
T 1.46 .07 0.98-2.19
0.93 .05 0.86-1.00
0.46 .005 0.26-0.79
0.88 .01 0.79-0.98
0.46 .01 0.25-0.84
T 2.28 .005 1.28-4.05
1192 Biol Blood Marrow Transplant 17:1187-1195, 2011K. Doney et al.survival (P 5 .007), increased RFS (P 5 .06), and de-
creased NRM (P 5 .01). A more recent date of HCT
also was associated with a lower relapse rate (P 5
.01) and improved RFS (P 5 .05). Mismatched do-
nor–recipient CMV serology pre-HCT (-/1 or 1/-)
was correlated with increased NRM (P 5 .005) and
decreased RFS (P 5 .07).
Relapse was most strongly associated with MRD
pre-HCT, as assessed by flow cytometry (P 5 .005).
If CR is redefined as the absence of cytogenetic,
FISH, or flow cytometric evidence of disease, in addi-
tion to BM that is .20% cellular with\5% morpho-
logically normal blasts, then actuarial survival at 5
years for the 74 patients undergoing HCT while in
any CR was 52% in patients without MRD and 29%
in those with MRD (P 5 .08). The corresponding
probabilities of relapse are 27% in patients with no
MRD and 44% in those with MRD (P 5 .06).DISCUSSION
In 2003,wepublished the results of 182 consecutive
adult ALL patients who underwent allogeneic HCT
with full-intensity conditioning between January
1990 and December 1997 [7]. In that study, the factors
most significantly associated with improved survival
and RFS were younger recipient age and being in
CR1 at the time of HCT. The predictive value of
markers of MRDwas not examined. In patients under-
going HCTwhile in CR1, RFS, NRM, and the proba-
bility of relapsewere 43%, 42%, and 15%, respectively,
at 5 years post-HCT.
There are several significant differences between
the current cohort of 161 patients and our previously
published data. In the current study, (1) median patient
age was greater (35.3 years vs 29.4 years; P5.0004), (2)
median disease duration from diagnosis to transplanta-
tion was less (8.5 months vs 13.3 months; P5.05), and
(3) the number of patients undergoing HCT while in
CR1 was higher (47% vs 23%; P\.0001). The major-
ity of the more recent transplants used unrelated
donors rather than HLA-matched, related donors
(P \.0001), and the criteria for identifying suitable
alternative donors have been refined [24].
Transplantation regimens also have changed over
time. Although the majority of our patients continued
to receive a Cy/TBI conditioning regimen, the method
of delivering TBI has changed from dual cobalt sources
to a linear accelerator with lung shielding. The source
of most stem cell infusions is now G-CSF‒mobilized
PBSCs rather than BM. In patients with Ph1 ALL,
tyrosine kinase inhibitor (TKI) therapy is being incor-
porated both before and after HCT [25-27].
Supportive care has improved with the availability
of more effective antiviral and antifungal agents and
more sensitive techniques for detecting reactivationof infection, including CMV PCR assays and serum
galactomannan levels [17,28]. Beginning in 2003,
ursodiol was added as a liver ‘‘protectant,’’ which has
resulted in a significant decrease in post-HCT hepatic
toxicity, including sinusoidal obstructive syndrome
and hepatic GVHD [18,19].
Despite these changes, however, the 5-year RFS in
our patients who underwent HCT while in CR1 was
similar in the 1990-1997 and 1998-2006 cohorts
(43% vs 47%). Whereas NRM decreased over time
(42% vs 21%), the probability of relapse increased
(15% vs 32%). Reasons for this increase in relapse
rate are not completely clear, although decreased early
deaths from nonrelapse causes allows more patients to
survive long enough to experience relapse.
Table 4 summarizes several studies of allogeneic
HCT in patients with ALL [2,7,29-33]. Most
previous reports have focused on patients in CR1 or
CR2 who had HLA-identical sibling donors. Pediatric
and adult patient outcomes are often reported to-
gether. Common to all studies is the use of hyperfrac-
tionated TBI, with total TBI doses of 12-15.75 Gy,
plus Cy or etoposide. Except for our current patient
cohort, BM has been the major source of stem cells.
The best outcomes are those reported by the Stanford
group in 2003 for patients in CR1 with HLA-matched
related donors and by the Medical Research Council/
Eastern Cooperative Oncology Group (MRC/
ECOG) E2993 study in 2008 for patients in CR1
with ‘‘standard risk’’ disease andHLA-matched related
donors [2,29]. These patients all receivedTBI followed
by etoposide rather than Cy. The Stanford study,
which included both pediatric and adult patients,
found a 10-year overall survival of 64%, NRM of
25%, and a relapse rate of 15%. In the MRC/
ECOG study, patients received uniform, intensive
induction and consolidation therapy pre-HCT, and
survival data were calculated from the time of diagno-
sis. Overall 5-year survival and relapse rates for the
standard-risk patients (i.e., age\35 years, WBC count
at diagnosis#30,000 109/L for patients with B-ALL,
and Ph-) were 62% and 24%, respectively, and the 2-
year NRM was 19.5%. Our patients received several
different induction regimens for a varying number of
cycles before being referred forHCT.Only 7 of our pa-
tients in CR1 with an HLA-matched sibling donor
were considered standard risk by theMRC/ECOGcri-
teria, because these patients were not routinely offered
early HCT.
Given the high relapse rates in our patients regard-
less of disease status pre-HCT, continued improve-
ment in RFS might depend on both earlier
identification and treatment of patients at high risk
for relapse. Our data suggest that pre-HCT flow
cytometric evidence of MRD is a sensitive marker sig-
nificantly associated with post-HCT relapse. Such
a marker could be used to identify patients for whom
Table 4. Myeloablative Allogeneic HCT for ALL
Group Study Dates n
Median Age,
Years (Range)
Remission
Status Donor Conditioning Regimen Stem Cell Source
Overall
Survival
Disease-Free
Survival NRM Relapse
Stanford*; Jamieson
et al. [29]
1987-2002 85 24 (0-48) in CR1; CR1 MRD 13.2 Gy TBI/VP16 BM (78); PBSCs (7) 66% 64% 25% 15%
10 (3-42) in CR2 CR2 62% 61% 15% 33%
CIBMTR/COH;
Marks et al. [30]
1989-1998 502 <25 (1-56) CR1 MRD Cy/TBI or VP16/TBI BM (466); PBSCs (36) 55%-62% 51%-61% 13%-27% 13%-33%
CR2 40%-72% 33%-62% 10%-20% 17%-46%
FHCRC; Doney et al. [7] 1990-1997 182 29 (18-57) CR1 MRD; URD;
MM
Cy/12-15.75 Gy TBI BM (158); PBSCs (19);
cord blood (1)
43% 42% 15%
$CR2 23% 46% 30%
Relapse 9% 9% 45%
Nine European Centers;
Kiehl et al. [31]
1990-2002 221 31 (17-62) CR1 MRD; URD 10-13.5 Gy TBI-based
(82%) or busulfan-based
(18%)
BM (110); PBSCs (111) 43%
CR2 23%
Relapse 3%-10%
First-degree
induction
failure
36%
MRC/ECOG†;
Goldstone et al. [2]
1993-2006 310 (NR 15-54) CR1, Ph-,
standard risk
MRD 13.2 Gy TBI/VP16 NR 62% 19.5% 24%
CR1, Ph-,
high risk
41% 35.85% 37%
COH/Stanford‡;
Laport et al. [32]
1985-2005 79 36 (2-57) CR1, Ph+ MRD 13.2 Gy TBI/VP16 (85%) or
13.2 Gy TBI/VP16/Cy
(14%)
BM (43); PBSCs (36) 54% 48% 54% 28%
$CR1, Ph+ 29% 26% 31% 41%
CIBMTR; Marks et al. [33] 1995-2006 1428 28 (16-62) CR1 MRD: URD:
MM
<13 Gy TBI (59%); $13 Gy
TBI (29%); Cy-based
(10%)
BM (817); PBSCs (611) 51% 49% 33% (CR1 +
CR2)
21%
CR2 33% 32% 31%
Present study 1998-2006 161 36 (18-61) CR1 MRD; URD;
MM
Cy/12-13.2 Gy TBI BM (47); PBSCs (110);
cord blood (4)
47% 21% 32%
$CR2 28% 35% 37%
Relapse 13% 46% 40%
MRD indicates HLA-matched related donor; URD, HLA-matched unrelated donor; MM, mismatched donor (related or unrelated); NR, not reported; CIBMTR, Center for International Blood and Marrow Transplant
Research; COH, City of Hope.
*Stanford outcome data are 10-year estimates.
†MRC/ECOG data measured from the time of diagnosis. MRC/ECOG NRM data are 2-year estimates, and OS and relapse data are 5-year estimates.
‡CIBMTR data are 3-year estimates.
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a more intensive transplantation preparative regimen
is warranted. For Ph1 patients who are being moni-
tored for MRD with an PCR-based assay, the efficacy
of adding TKI therapy during induction and consoli-
dation therapy will help answer this question [25,26].
For Ph- patients with evidence of MRD pre-HCT,
the intensification of transplantation regimens with
such approaches as radiolabeled immunotherapy is
currently being tested [34].
Post-HCT monitoring for MRD also may prove
important in guiding early post-HCT intervention
for MRD, such as earlier manipulation of GVHD to
maximize a graft-versus-leukemia effect. This ap-
proach has met with varying success. In 2004, Kiehl
et al. [31] published outcome data for 264 adults with
ALL who received full-intensity conditioning stem
cell transplantation. A significant increase in disease-
free survival was seen in those patients who developed
grade I-II aGVHD compared with those without
aGVHD or with grade III-IV aGVHD. The effect of
cGVHD was not addressed. The authors concluded
that there was a ‘‘strong’’ graft-versus-leukemia effect.
Also in 2004, Nordlander et al. [35] analyzed outcomes
of full-intensity conditioning HCT in 199 patients
with ALL, both pediatric and adult. In univariate anal-
yses, the presence of any aGVHD or cGVHD (not
otherwise defined) was significantly associated with
a decreased probability of relapse. In the correspond-
ing multivariate analysis, the absence of cGVHD was
associated with a 3.9-fold increased risk of relapse. In
our current univariate analyses, only grade III-IV
aGVHD was associated with a statistically significant
decrease in the probability of relapse. This association
was not maintained in the multivariate analysis, how-
ever. Older analyses of multicenter data also have re-
ported divergent results in terms of a significant
association between aGCHD or cGVHD and relapse
rates [36-39].
In Ph1 ALL patients, the reinstitution of TKI
therapy early after HCT as maintenance therapy,
with PCR-based assays used to assess response, is un-
der study [27]. Options for either maintenance therapy
or other therapeutic intervention at the first sign of
MRD are limited for other patients at high risk for re-
lapse, however. Approaches under active investigation
include reinstitution of conventional chemotherapy,
unconjugated or conjugated monoclonal antibodies,
and adoptive cellular therapies, including donor lym-
phocyte infusion and cytotoxic T lymphocyte clones
that recognize leukemia-associated antigens [40].
Early second transplantations using a nonmyeloabla-
tive regimen is feasible in some cases.
In summary, post-HCT relapse remains the major
cause of morbidity and mortality in our adult ALL
population, regardless of disease status pre-HCT.His-
torically, disease status has been defined by morpho-logical criteria only. With the advent of sensitive
assays to detect MRD that correlate with relapse after
HCT, greater attention should be focused both on
minimizing the disease burden pre-HCT and on
developing more aggressive approaches to treating
MRD early in the pos-HCT setting.ACKNOWLEDGMENTS
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